Hutchison China MediTech : Chi-Med to Present at JP Morgan Conference

RNS Reach Story
Go to market news section
Hutchison China Meditech Limited - HCM Chi-Med to Present at JP Morgan Conference Released 07:04 06-Jan-2020

RNS Number : 8109Y

Hutchison China Meditech Limited

06 January 2020

Press Release Chi-Med to Present at the 38^th Annual JP Morgan Healthcare Conference

London: Monday, January 6, 2020:Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38^th Annual JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA.

The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under 'Events, Circulars & Forms.' Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 490 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	[phone]
Annie Cheng, Vice President	[phone]
David Dible, Citigate Dewe Rogerson	[phone] (Mobile)[e-mail]
Xuan Yang, Solebury Trout	[phone] (Mobile) [e-mail]
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson	[phone] (Mobile) [e-mail]
Americas- Brad Miles, Solebury Trout	[phone] (Mobile) [e-mail]
Hong Kong & Asia ex-China	- Joseph Chi Lo, Brunswick	[phone] (Mobile) [e-mail]
	- Zhou Yi, Brunswick	[phone](Mobile) [e-mail]
Mainland China- Sam Shen, Edelman	[phone] (Mobile) [e-mail]
Nominated Advisor
Atholl Tweedie, Panmure Gordon (UK) Limited	[phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAKKABKOBKKKDK

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2014London Stock Exchange plc. All rights reserved

Chi-Med to Present at JP Morgan Conference - RNS